The KWTRP Data Repository helps researchers make data linked to published works and research studies available for reuse. It also facilitates long-term preservation of research data and reproducibility of reported findings. Data are hosted as open or restricted access. Restricted datasets require submission of a data request to our data governance committee for consideration and approval.

Useful Links:

  1. Data Sharing Policy
  2. Data Request Form

COVID-19 Data Resources

Search, request and download our curated collection of COVID-19 datasets.

Metrics

alternative text alternative text: oval alternative text: oval

Download Full Report

Featured Dataverses

In order to use this feature you must have at least one published or linked dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

71 to 80 of 2,527 Results
Data_Readme E cohort.txt
May 6, 2025 - Building the Evidence Base for Health System Transformation Through Designing and Testing of Future Health System Models and Measure: PNC Data
Plain Text - 4.2 KB - MD5: 41069e7d0c5e9830e6014d530047865f
Documentation
PNCdataset.tab
May 6, 2025 - Building the Evidence Base for Health System Transformation Through Designing and Testing of Future Health System Models and Measure: PNC Data
Tabular Data - 181.6 KB - 68 Variables, 792 Observations - UNF:6:NZp9At7rhRTvhWYDWOU7Ow==
Data
SPIRIT 2013 Checklist: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
May 2, 2025 - Human Genetic Factors (HGF) Group
Williams, Tom, 2025, "SPIRIT 2013 Checklist: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013", https://doi.org/10.7910/DVN/QUGG6P, Harvard Dataverse, V3
Package includes a SPIRIT checklist and Trial assessment schedule. Trial Registration Number: ISRCTN 15724013
pactr.samrc.ac.za_TrialDisplay.aspx_TrialID=25747.pdf
May 2, 2025 - SPIRIT 2013 Checklist: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
Adobe PDF - 287.7 KB - MD5: 3c30329ab7845566fcd1f5a766b1e880
PACTR Registration File
Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
May 2, 2025 - Human Genetic Factors (HGF) Group
Williams, Tom, 2025, "Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013", https://doi.org/10.7910/DVN/DKR3LX, Harvard Dataverse, V1
The package contains extended data for the protocol titled "Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013"
101_H-PRIME patient information sheet ΓÇô parents and carers v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 165.6 KB - MD5: a3e388b1ebfece28d4b38e47d9ae6018
102_H-PRIME TRIAL patient information sheet older children v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 50.5 KB - MD5: 205b0f38f7a4b77982d3aef0f5c12583
103_H-PRIME consent form for screening v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 164.6 KB - MD5: 73030510d7d650507b9e1866f1813ef7
104_H-PRIME TRIAL consent form - parents and carers v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 163.7 KB - MD5: 41d9c14e32a845e764955f5334667d1e
105_H-PRIME TRIAL assent form v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 164.4 KB - MD5: 1e1a43dded6ac06e350a7d7460f4dc99
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.